BioSpace News Archive

Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced the acceptance of an abstract on TPST-1495, a EP2/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.

Telix Pharmaceuticals Limited announces the expansion of its artificial intelligence capability with the signing of an agreement to acquire Vienna-based Dedicaid GmbH, a spin-off of the Medical University Vienna.

Dizal announced that multiple clinical data of its two leading assets – sunvozertinib and golidocitinib have been selected for presentations at the 2023 ASCO, June 2-6, 2023 in Chicago.

Scott Arnold, executive vice president and chief information officer of Tampa General Hospital, has been named a top health care information technology leader by Becker’s Hospital Review on its 2023 “CIOs to Know” list.

Baudax Bio, Inc. announced the pricing of its public offering of an aggregate of 3,478,262 shares of its common stock, together with accompanying common stock purchase warrants, at a public offering price of $1.15 per share and accompanying warrants.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2023 Healthcare Conference.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary Curetis GmbH has met the remaining key milestones under the initial research and development collaboration agreement with FIND.

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced the acceptance of a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL.

Calliditas Therapeutics AB announces that the Annual Report for 2022 now is available at the company’s website.